Looking ahead to 2025, small biopharma will continue its deliberate and ROI-driven approach to technology adoption. At the ...

While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...

Industry 4.0-enabled techniques like automation and artificial intelligence can make process development more cost-effective.

Beyond that optimism, the executives laid out four areas of particular concern in the coming year, including leveraging the industry's ongoing digital ... than half of the biopharma executives ...

“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...

At the center of this transformation is expected to be the adoption of artificial intelligence, digital and medical technologies. However, challenges in the NHS around its ‘core technology’, data ...